Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer

Published:2021-08 Issue: Volume:162 Page:S24-S25
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Matulonis Ursula,Herrstedt Jørn,Oza Amit,Mahner Sven,Redondo Andrés,Berton Dominique,Berek Jonathan,Lund Bente,Marmé Frederik,González-Martín Antonio,Tinker Anna,Ledermann Jonathan,Benigno Benedict,Lindahl Gabriel,Colombo Nicoletta,Li Yong,Gupta Divya,Monk Bradley,Mirza Mansoor

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Germline BRCA pathogenic variants in patients with ovarian cancer and post-poly (ADP-ribose) polymerase inhibitor myeloid neoplasms;ESMO Open;2024-09

2. PARP Inhibitors in Brain Metastases from Epithelial Ovarian Cancer through a Multimodal Patient Journey: Case Reports and Literature Review;International Journal of Molecular Sciences;2024-07-18

3. Feasibility and cost-effectiveness of genetic counselling for all patients with newly diagnosed ovarian cancer: a single-centre retrospective study;Swiss Medical Weekly;2024-04-15

4. PARP inhibitors in ovarian cancer;Seminars in Oncology;2024-02

5. A real-world study of PARP inhibitors in 75 patients with platinum-sensitive recurrent ovarian cancer from China;Frontiers in Oncology;2024-01-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP